Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9748796rdf:typepubmed:Citationlld:pubmed
pubmed-article:9748796lifeskim:mentionsumls-concept:C0596382lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C0678222lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C0013089lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C0085533lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C0950521lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C0015737lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C0205265lld:lifeskim
pubmed-article:9748796lifeskim:mentionsumls-concept:C1555582lld:lifeskim
pubmed-article:9748796pubmed:issue1lld:pubmed
pubmed-article:9748796pubmed:dateCreated1998-10-29lld:pubmed
pubmed-article:9748796pubmed:abstractTextThe aim of this multicentric, prospective randomized trial is to evaluate and to compare, effects and toxicities of two chemotherapeutic combinations (AC and CMF) in adjuvant treatment of breast cancer. Both combinations were given in equitoxic doses and number of cycles was only four. There are 106 women treated for breast cancer T1c-3a, N0-1, M0 in the study. After surgery the patients were randomized, 54 for AC combination and 52 for CMF. We evaluate toxicity of this treatment in all patients in the study. Hematological and nonhematological side effects were comparable in both groups except alopecia (in the group AC was 100%). The study is not finished yet. Preliminary analysis does not show any difference between these two groups.lld:pubmed
pubmed-article:9748796pubmed:languageczelld:pubmed
pubmed-article:9748796pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9748796pubmed:citationSubsetIMlld:pubmed
pubmed-article:9748796pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9748796pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9748796pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9748796pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9748796pubmed:statusMEDLINElld:pubmed
pubmed-article:9748796pubmed:issn0036-5327lld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:FischerJJlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:BauerJJlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:DorazilováVVlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:VodvárkaPPlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:MillerVVlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:KohoutekMMlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:SurSSlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:KyseláTTlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:MachácekJJlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:PetruzelkaLLlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:PribylovàHHlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:HonováHHlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:BustováIIlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:SiffnerováHHlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:K?taMMlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:HacklováMMlld:pubmed
pubmed-article:9748796pubmed:authorpubmed-author:TajblováJJlld:pubmed
pubmed-article:9748796pubmed:issnTypePrintlld:pubmed
pubmed-article:9748796pubmed:volume99lld:pubmed
pubmed-article:9748796pubmed:ownerNLMlld:pubmed
pubmed-article:9748796pubmed:authorsCompleteYlld:pubmed
pubmed-article:9748796pubmed:pagination25-31lld:pubmed
pubmed-article:9748796pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:9748796pubmed:meshHeadingpubmed-meshheading:9748796-...lld:pubmed
pubmed-article:9748796pubmed:meshHeadingpubmed-meshheading:9748796-...lld:pubmed
pubmed-article:9748796pubmed:meshHeadingpubmed-meshheading:9748796-...lld:pubmed
pubmed-article:9748796pubmed:meshHeadingpubmed-meshheading:9748796-...lld:pubmed
pubmed-article:9748796pubmed:meshHeadingpubmed-meshheading:9748796-...lld:pubmed
pubmed-article:9748796pubmed:meshHeadingpubmed-meshheading:9748796-...lld:pubmed
pubmed-article:9748796pubmed:meshHeadingpubmed-meshheading:9748796-...lld:pubmed
pubmed-article:9748796pubmed:meshHeadingpubmed-meshheading:9748796-...lld:pubmed
pubmed-article:9748796pubmed:meshHeadingpubmed-meshheading:9748796-...lld:pubmed
pubmed-article:9748796pubmed:meshHeadingpubmed-meshheading:9748796-...lld:pubmed
pubmed-article:9748796pubmed:meshHeadingpubmed-meshheading:9748796-...lld:pubmed
pubmed-article:9748796pubmed:year1998lld:pubmed
pubmed-article:9748796pubmed:articleTitle[Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study].lld:pubmed
pubmed-article:9748796pubmed:affiliationOnkologická klinika Vseobecné fakultní nemocnice v Praze a 1. lékarské fakulty Univerzity Karlovy, Praha.lld:pubmed
pubmed-article:9748796pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9748796pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9748796pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9748796pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:9748796pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:9748796pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:9748796pubmed:publicationTypeMulticenter Studylld:pubmed